Compare PLUR & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUR | NOTV |
|---|---|---|
| Founded | 2001 | 1974 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 23.0M |
| IPO Year | N/A | 1997 |
| Metric | PLUR | NOTV |
|---|---|---|
| Price | $3.03 | $0.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $3.00 |
| AVG Volume (30 Days) | 20.6K | ★ 463.7K |
| Earning Date | 02-10-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,326,000.00 | ★ $513,024,000.00 |
| Revenue This Year | $97.38 | $6.49 |
| Revenue Next Year | $293.97 | $4.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 121.74 | 4.54 |
| 52 Week Low | $2.82 | $0.47 |
| 52 Week High | $7.13 | $4.80 |
| Indicator | PLUR | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 36.56 |
| Support Level | $3.01 | $0.54 |
| Resistance Level | $3.21 | $0.58 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 33.15 | 18.23 |
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.